| Literature DB >> 34098897 |
Yanlei Wang1, Guohui Wang1, Zheng Li1, Hao Ling1, Bo Yi2, Shaihong Zhu3.
Abstract
BACKGROUND: The Micro Hand S robot is a new surgical tool that has been applied to total mesorectal excision (TME) surgery for rectal cancer in our center. In this study, we compared the operative outcomes, functional outcomes and learning curves of the Micro Hand S robot-assisted TME (RTME) with laparoscopic TME (LTME).Entities:
Keywords: Laparoscopic surgery; Micro Hand S surgical robot system; Rectal cancer; Robotic surgery; Total mesorectal excision
Mesh:
Year: 2021 PMID: 34098897 PMCID: PMC8186043 DOI: 10.1186/s12876-021-01834-1
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1The Micro Hand S surgical robotic system. Surgeon console (right): (1) image display device, (2) master arm, (3) control panel. 3D imaging system (middle). Slave surgical cart (left): (4) electrical control system, (5) lifting column, (6) suspension passive arm, (7) swivel head, (8) slave arm
Fig. 2The flow chart of patient selection
Fig. 3The arrangement of the surgical ports for RTME
Patient characteristics and clinicopathological outcomes between RTME and LTME
| RTME (n = 40) | LTME (n = 65) | ||
|---|---|---|---|
| Age (year) | 57.4 ± 9.5 | 60.2 ± 10.8 | 0.178 |
| Male | 20 (50.0) | 31 (47.7) | 0.818 |
| BMI (kg/m2) | 21.8 ± 2.9 | 22.2 ± 4.2 | 0.577 |
| ASA (I/II/III) | 19/16/5 (47.5/40.0/12.5) | 23/28/14 (35.4/43.1/21.5) | 0.353 |
| Distance from AV (cm) | 8.2 ± 2.9 | 7.5 ± 3.2 | 0.299 |
| CRT | 5 (12.5) | 5 (7.7) | 0.415 |
| 1.000 | |||
| LAR | 38 (95.0) | 61 (93.8) | |
| APR | 2 (5.0) | 4 (6.2) | |
| Operative time (min) | 339.3 ± 45.3 | 320.8 ± 52.8 | 0.070 |
| Blood loss (ml) | 140.9 ± 68.5 | 188.0 ± 73.0 | 0.001 |
| Conversion | 1 (2.5) | 3 (4.6) | 1.000 |
| Protective ileostomy | 22 (55.0) | 31 (51.7) | 0.744 |
| Hospital stay (day) | 9.2 ± 3.8 | 11.9 ± 3.9 | 0.001 |
| Tumor size (cm) | 3.4 ± 1.4 | 3.8 ± 1.5 | 0.240 |
| Retrieved lymph node | 15.3 ± 4.9 | 15.6 ± 5.3 | 0.774 |
| pTNM (I/II/III) | 4/11/25 (10.0/27.5/62.5) | 13/15/37 (20.0/23.1/56.9) | 0.395 |
| DRM (cm) | 2.4 ± 1.3 | 2.5 ± 1.5 | 0.804 |
| Involved DRM | 0 | 0 | – |
| Involved CRM | 2 (5.0) | 0 | 0.143 |
| 0.846 | |||
| Poor | 12 (30.0) | 15 (23.1) | |
| Moderate | 17 (42.5) | 30 (46.2) | |
| Well | 8 (20.0) | 13 (20.0) | |
| Others | 5 (12.5) | 7 (10.7) | |
| 0.897 | |||
| Complete | 31 (77.5) | 48 (73.8) | |
| Nearly complete | 6 (15.0) | 12 (18.5) | |
| Incomplete | 3 (7.5) | 5 (7.7) |
BMI body mass index, ASA American Society Anesthesia, AV anal verge, CRT chemoradiation therapy, LAR low anterior resection, APR abdominal perineal resection, DRM distal resection margin, CRM circumferential resection margin, TME total mesorectal excision. Values are presented as mean ± standard deviation, n or n (%)
Postoperative complications between RTME and LTME
| RTME (n = 40) | LTME (n = 65) | ||
|---|---|---|---|
| 12 (30.0) | 23 (35.4) | 0.570 | |
| Wound complication | 2 (5.0) | 5 (7.7) | 0.706 |
| Fluid collection | 3 (7.5) | 3 (4.6) | 0.672 |
| Ileus | 1 (2.5) | 4 (6.2) | 0.647 |
| Urinary retention | 2 (1.9) | 3 (4.6) | 1.000 |
| Pneumonia | 0 | 2 (3.1) | 0.524 |
| Pulmonary failure | 0 | 1 (1.5) | 1.000 |
| Anastomotic bleeding | 2 (1.9) | 3 (4.6) | 1.000 |
| Anastomotic leakage | 1 (2.5) | 1 (1.5) | 1.000 |
| Intraabdominal abscess | 0 | 1 (1.5) | 1.000 |
| Anterior resection syndrome | 1 (2.5) | 0 | 0.381 |
| C–D grade (III–V) | 3 (7.5) | 4 (6.2) | 1.000 |
C–D Clavien–Dindo. Values are presented as n (%)
Comparison of functional outcomes between RTME and LTME in male patients
| RTME (n = 13) | LTME (n = 22) | ||
|---|---|---|---|
| Pre-operation | 5.3 ± 3.5 | 6.2 ± 3.6 | 0.494 |
| 3 Months | 9.6 ± 5.0 | 10.2 ± 5.3 | 0.759 |
| | 0.019 | 0.006 | |
| 6 months | 7.9 ± 4.0 | 8.4 ± 4.3 | 0.743 |
| | 0.091 | 0.072 | |
| 12 months | 7.0 ± 3.5 | 7.8 ± 3.9 | 0.557 |
| | 0.230 | 0.168 | |
| Pre-operation | 15.8 ± 5.6 | 15.1 ± 5.3 | 0.740 |
| 3 Month | 10.8 ± 4.0 | 9.9 ± 5.1 | 0.609 |
| | 0.015 | 0.002 | |
| 6 months | 13.0 ± 4.4 | 12.3 ± 5.3 | 0.679 |
| | 0.174 | 0.080 | |
| 12 months | 14.5 ± 5.4 | 13.2 ± 5.2 | 0.483 |
| | 0.575 | 0.235 |
IPSS International Prostate Symptom Score, IIEF International Index of Erectile Function. Values are presented as mean ± standard deviation
Fig. 4The IPSS score for RTME and LTME in male patients. *p < 0.05 for difference in mean scores between preoperatively and each time point
Fig. 5The IIEF-5 score for RTME and LTME in male patients. *p < 0.05 for difference in mean scores between preoperatively and each time point
Fig. 6The learning curves for RTME and LTME. The curve of RTME reached the peak point at the 17th case; and the curve of LTME reached the peak point at the 34th case
Comparison of the learning curve phases: RTME versus LTME
| Phase 1 (n = 51) | Phase 2 (n = 54) | |||||
|---|---|---|---|---|---|---|
| RTME (n = 17) | LTME (n = 34) | RTME (n = 23) | LTME (n = 31) | |||
| Age (year) | 56.2 ± 9.5 | 60.1 ± 10.1 | 0.189 | 58.3 ± 9.6 | 60.3 ± 11.7 | 0.500 |
| Male | 8 (47.1) | 16 (47.1) | 1.000 | 12 (52.2) | 15 (48.4) | 0.783 |
| BMI (kg/m2) | 21.8 ± 2.9 | 22.8 ± 4.7 | 0.414 | 21.8 ± 3.0 | 21.5 ± 3.5 | 0.735 |
| ASA (I/II/III) | 6/9/2 (35.3/52.9/11.8) | 13/15/6 (38.2/44.1/17.7) | 0.793 | 13/7/3 (56.5/30.4/13.1) | 10/13/8 (32.3/41.9/25.8) | 0.187 |
| Distance from AV (cm) | 8.1 ± 3.1 | 7.6 ± 3.2 | 0.588 | 8.3 ± 2.9 | 7.5 ± 3.4 | 0.375 |
| CRT | 1 (5.9) | 3 (8.8) | 1.000 | 4 (17.4)) | 2 (6.5) | 0.384 |
| 1.000 | 1.000 | |||||
| LAR | 16 (94.1) | 32 (94.1) | 22 (95.7) | 29 (93.5) | ||
| APR | 1 (5.9) | 2 (5.9) | 1 (4.3) | 2 (6.5) | ||
| Operative time (min) | 360.6 ± 40.8 | 338.1 ± 47.2 | 0.100 | 323.5 ± 42.6 | 301.9 ± 52.8 | 0.114 |
| Blood loss (ml) | 148.2 ± 73.8 | 195.0 ± 62.4 | 0.022 | 135.4 ± 65.4 | 180.3 ± 83.5 | 0.037 |
| Conversion | 1 (5.9) | 2 (5.9) | 1.000 | 0 | 1 (3.2) | 1.000 |
| Protective ileostomy | 11 (64.7) | 19 (63.3) | 0.925 | 11 (47.8) | 12 (40.0) | 0.569 |
| Hospital stay (day) | 9.5 ± 3.7 | 12.2 ± 3.5 | 0.017 | 9.0 ± 4.0 | 11.6 ± 4.4 | 0.029 |
| C–D grade (III–V) | 1 (5.9) | 2 (5.9) | 1.000 | 2 (8.7) | 2 (6.5) | 1.000 |
| Tumor size (cm) | 3.3 ± 1.2 | 3.5 ± 1.4 | 0.602 | 3.5 ± 1.6 | 4.0 ± 1.6 | 0.221 |
| Retrieved lymph node | 15.2 ± 4.8 | 16.7 ± 5.7 | 0.369 | 15.4 ± 5.0 | 14.5 ± 4.8 | 0.485 |
| pTNM (I/II/III) | 1/4/12 (5.9/23.5/70.6) | 5/7/22 (14.7/20.6/64.7) | 0.652 | 3/7/13 (13.1/30.4/56.5) | 8/8/15 (25.8/25.8/48.4) | 0.515 |
| DRM (cm) | 2.4 ± 1.3 | 2.7 ± 1.5 | 0.545 | 2.4 ± 1.4 | 2.3 ± 1.5 | 0.757 |
| Involved DRM | 0 | 0 | – | 0 | 0 | – |
| Involved CRM | 1 (5.9) | 0 | 0.333 | 1 (4.3) | 0 | 0.426 |
| 0.933 | 0.858 | |||||
| Complete | 12 (70.6) | 23 (67.6) | 19 (82.6) | 25 (80.6) | ||
| Nearly complete | 4 (23.5) | 8 (23.5) | 2 (8.7) | 4 (12.9) | ||
| Incomplete | 1 (5.9) | 3 (8.8) | 2 (8.7) | 2 (6.5) | ||
BMI body mass index, ASA American Society Anesthesia, AV anal verge, CRT chemoradiation therapy, LAR low anterior resection, APR abdominal perineal resection, DRM distal resection margin, CRM circumferential resection margin, TME total mesorectal excision. Values are presented as mean ± standard deviation or n (%)
Comparison of the learning curve phases: Phase 1 versus Phase 2
| RTME (n = 40) | LTME (n = 65) | |||||
|---|---|---|---|---|---|---|
| Phase 1 (n = 17) | Phase 2 (n = 23) | Phase 1 (n = 34) | Phase 2 (n = 31) | |||
| Age (year) | 56.2 ± 9.5 | 58.3 ± 9.6 | 0.500 | 60.9 ± 10.0 | 60.3 ± 11.7 | 0.941 |
| Male | 8 (47.1) | 12 (52.2) | 0.749 | 16 (47.1) | 15 (48.4) | 0.915 |
| BMI (kg/m2) | 21.8 ± 2.9 | 21.8 ± 3.0 | 0.962 | 22.8 ± 4.7 | 21.5 ± 3.5 | 0.217 |
| ASA (I/II/III) | 6/9/2 (35.3/52.9/11.8) | 13/7/3 (56.5/30.4/13.1) | 0.337 | 13/15/6 (38.2/44.1/17.7) | 10/13/8 (32.3/41.9/25.8) | 0.711 |
| Distance from AV (cm) | 8.1 ± 3.1 | 8.3 ± 2.9 | 0.856 | 7.6 ± 3.2 | 7.5 ± 3.4 | 0.897 |
| CRT | 1 (5.9) | 4 (23.0) | 0.373 | 3 (8.8) | 2 (6.5) | 1.000 |
| 1.000 | 1.000 | |||||
| LAR | 16 (94.1) | 22 (95.7) | 32 (94.1) | 29 (93.5) | ||
| APR | 1 (5.9) | 1 (4.3) | 2 (5.9) | 2 (6.5) | ||
| Operative time (min) | 360.6 ± 40.8 | 323.5 ± 42.6 | 0.009 | 338.1 ± 47.2 | 301.9 ± 52.8 | 0.005 |
| Blood loss (ml) | 148.2 ± 73.8 | 135.4 ± 65.4 | 0.566 | 195.0 ± 62.4 | 180.3 ± 83.5 | 0.422 |
| Conversion | 1 (5.9) | 0 | 0.425 | 2 (5.9) | 1 (3.2) | 1.000 |
| Protective ileostomy | 11 (64.7) | 11 (47.8) | 0.289 | 19 (63.3) | 12 (40.0) | 0.071 |
| Hospital stay (day) | 9.5 ± 3.7 | 9.0 ± 4.0 | 0.644 | 12.2 ± 3.5 | 11.6 ± 4.3 | 0.544 |
| C–D grade (III–V) | 1 (5.9) | 2 (8.7) | 1.000 | 2 (5.9) | 2 (6.5) | 1.000 |
| Tumor size (cm) | 3.3 ± 1.2 | 3.5 ± 1.6 | 0.707 | 3.5 ± 1.4 | 4.0 ± 1.6 | 0.166 |
| Retrieved lymph node | 15.2 ± 4.8 | 15.4 ± 5.0 | 0.892 | 16.7 ± 5.7 | 14.5 ± 4.8 | 0.099 |
| pTNM (I/II/III) | 1/4/12 (5.9/23.5/70.6) | 3/7/13 (13.1/30.4/56.5) | 0.613 | 5/7/22 (14.7/20.6/64.7) | 8/8/15 (25.8/25.8/48.4) | 0.377 |
| DRM (cm) | 2.4 ± 1.3 | 2.4 ± 1.4 | 0.964 | 2.7 ± 1.5 | 2.3 ± 1.5 | 0.346 |
| Involved DRM | 0 | 0 | – | 0 | 0 | – |
| Involved CRM | 1 (5.9) | 1 (4.3) | 1.000 | 0 | 0 | – |
| 0.423 | 0.477 | |||||
| Complete | 12 (70.6) | 19 (82.6) | 23 (67.6) | 25 (80.6) | ||
| Nearly complete | 4 (23.5) | 2 (8.7) | 8 (23.5) | 4 (12.9) | ||
| Incomplete | 1 (5.9) | 2 (8.7) | 3 (8.8) | 2 (6.5) | ||
BMI body mass index, ASA American Society Anesthesia, AV anal verge, CRT chemoradiation therapy, LAR low anterior resection, APR abdominal perineal resection, DRM distal resection margin, CRM circumferential resection margin, TME total mesorectal excision. Values are presented as mean ± standard deviation or n (%)